Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00645463
Recruitment Status : Completed
First Posted : March 27, 2008
Last Update Posted : September 17, 2009
Information provided by:

Brief Summary:

A recently completed clinical drug interaction study of CP-945,598 with ketoconazole, a potent CYP3A inhibitor, showed that coadministration of CP-945,598 with ketoconazole results in an approximately 5-fold increase in CP-945,598 total exposure (AUC) and 4-fold increase in Cmax. Therefore, the sensitivity of CP-945,598 pharmacokinetics (PK) to less potent CYP3A inhibitors needs to be characterized to support labeling and registration.

Diltiazem is a known substrate and moderate mechanism-based inhibitor of the CYP3A enzyme system and was chosen as the moderate CYP3A inhibitor for this study as it is a clinically relevant medication likely to be prescribed concomitantly with CP-945,598 given the increased risk of hypertension and cardiovascular disease in the obese patient population.

Condition or disease Intervention/treatment Phase
Obesity Drug: CP-945,598 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Modified Release Diltiazem On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects
Study Start Date : March 2007
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group A Drug: CP-945,598
20 mg CP-945,598 + 240 mg MR Diltiazem

Experimental: Group B Drug: CP-945,598
20 mg CP-945,598 alone

Primary Outcome Measures :
  1. Pharmacokinetic parameters of CP-945,598 and its metabolite, CE-156,706, (AUCtau, Cmax and Tmax) [ Time Frame: Days 7 and 28 ]
  2. Safety endpoints including adverse event monitoring, physical examinations, vital signs, ECGs, and clinical laboratory tests. [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically relevant abnormalities based upon medical history, physical exam, 12-lead ECG, and clinical lab tests
  • Body Mass Index (BMI) ~ 27-40 kg/m2, inclusive
  • Personally signed inform consent document

Exclusion Criteria:

  • Evidence or history of significant acute or chronic disease
  • Pregnant or nursing females
  • Screening PR interval > 220 msec
  • Sitting blood pressure <= 90 mmHg systolic or <= 60 mmHg diastolic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00645463

United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48105
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00645463     History of Changes
Other Study ID Numbers: A5351043
First Posted: March 27, 2008    Key Record Dates
Last Update Posted: September 17, 2009
Last Verified: March 2008

Additional relevant MeSH terms:
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents